New options for the management of castration-resistant prostate cancer: A case perspective

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue SUPPL. 3, 2011, Pages

  Goetz, Dawn ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Abiraterone acetate; Cabazitaxel; Castration resistant; Chemotherapy; Docetaxel; Hormone therapy; Hormone refractory; Immunotherapy; Prostate cancer; Sipuleucel T

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; AMINOGLUTETHIMIDE; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; DASATINIB; DOCETAXEL; IPILIMUMAB; KETOCONAZOLE; LEUPRORELIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; ZOLEDRONIC ACID;

AGED; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; CANCER RADIOTHERAPY; CASE REPORT; CASTRATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHILL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HORMONAL THERAPY; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOTHERAPY; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; STROKE;

EID: 79952720160     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0128     Document Type: Article

References (31)

1. Prostate cancer facts & figures 2010. American Cancer Society Web site. Available at: http://www.cancer.org. Accessed October 22, 2010.
2. Stavridi F, Karapanagiotou EM, Syrigos KN. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 2010;36:122-130.
3. Hoimes CJ, Kelly WK. Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol 2010;2:107-123.
4. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-8261. (Pubitemid 46211563)
5. Nelson WG, De Marzo AM, Issacs WB. Mechanisms of disease: prostate cancer. N Engl J Med 2003;349:366-381.
6. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-1013. (Pubitemid 34160279)
7. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764. (Pubitemid 26185452)
8. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512. (Pubitemid 39315317)
9. Tolcher AW, Cooper J. Castration-resistant prostate cancer - hormone therapy redux. J Clin Oncol 2010;28:1447-1449.
10. Raghavan D, Klein EA. Prostate cancer: moving forward by reinventing the wheel...but this time it is round. J Clin Oncol 2008;26:4535-4536.
11. Patten DY, Sartor O. New therapeutic agents for castration-refractory prostate cancer. Clin Genitourin Cancer 2009;7:E4-E6.
12. Danila D, Rathcompf D, Morris M, et al. Abiraterone acetate and prednisone in patients with progressive castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy [abstract]. J Clin Oncol 2008;26(Suppl):Abstract 5019.
13. Bono JS, Logothetis CJ, Fizazi K, et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (MCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized double-blind placebo-controlled phase III study [abstract]. Ann Oncol 2010;21(Suppl 8):Abstract LBA5.
14. Lorenzo GD, Buonerba C, Autorino R, et al. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010;70:983-1000.
15. Arlen PM, Mohebtash M, Madan RA, Gulley JL. Promising novel immunotherapies and combinations for prostate cancer. Future Ocol 2009;5:187-196.
16. Harzstark AL, Small EJ. Immunotherapeutics in development for prostate cancer. Oncologist 2009;14:391-398.
17. Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer. Oncologist 2006;11:451-462. (Pubitemid 43788271)
18. Richwine L. U.S. FDA OKs Dendreon's prostate cancer vaccine. Reuters. April 29, 2010. Available at: http://www.reuters.com/article/ idUSN2919838820100429. Accessed April 30, 2010.
19. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
20. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-3094. (Pubitemid 46638945)
21. Provenge (sipuleuel-T) for advanced prostate cancer. Pharmacist's Letter/Prescriber's Letter, June 2010; Volume 26, Number 260612.
22. NCA Tracking Sheet for Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer (CAG-00422N). Centers for Medicare and Medicaid Services Web site. Available at: http://www.cms.gov/mcd/viewtrackingsheet.asp? from2=viewtrackingsheet. asp&id=247&. Accessed November 8, 2010.
23. Dendreon Statement on CMS National Coverage Analysis. PRNewswire Web site. Available at: http://www.prnewswire.com/news-releases/dendreon-statement- on-cms-national-coverageanalysis-97531459.html. Accessed on June 30, 2010.
24. Stein R. Review of prostate cancer drug Provenge renews medical costbenefit debate. The Washington Post, November 8, 2010. Available at: http://www.washingtonpost.com/wp-dyn/content/article/2010/11/07/AR2010110705205. html. Accessed November 8, 2010.
25. Provenge (sipuleucel-T) [package insert]. Seattle, WA: Dendreon Corporation; 2010.
26. Mohler J, Armstrong AJ, Bahnson RR, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2, 2010. Available at: http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed October 22, 2010.
27. Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review. PRNewswire Web site. Available at: http://www.prnewswire.com/news- releases/jevtana-cabazitaxel-injection-approved-by-us-fdaafter-priority-review- 96589609.html. Accessed on October 24, 2010.
28. Jevtana (cabazitaxel) [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LCC; June 2010.
29. de Bono JS, Oudard S, Ozgouroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-1154.
30. PACT+ Provider Portal. Available at: https://www.pactplusonline.com. Accessed on November 8, 2010.
31. Clinicaltrials.gov Web site. Available at: http://www.clinicaltrials.gov. Accessed on 10/25/2010.